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CD2BP1 and CARD15 Mutations Are Not Associated with
Pyoderma Gangrenosum in Patients with Inﬂammatory
Bowel Disease
To the Editor:
Pyoderma gangrenosum (PG) represents a rare, non-
infectious form of skin ulceration first formally described in
1930 (Brunsting et al, 1930). The lesion classically begins as
a painful papule, which progressively shows central ulcera-
tion with indeterminate borders and surrounding erythema.
The etiology of PG remains obscure, but in more than 50%
of cases this condition arises in association with immuno-
logic diseases, such as rheumatoid arthritis, diabetes
mellitus and inflammatory bowel disease, and therefore
appears to be at least partially attributable to immune dys-
function. While Mendelian inheritance of PG has not been
demonstrated, reports of families with multiple affected
members suggest that genetic factors are etiologically
important (Shands et al, 1987; al-Rimawi et al, 1996;
Khandpur et al, 2001; Alberts et al, 2002; Goncalves et al,
2002). This possibility is supported by the recent identifica-
tion of mutations in the gene encoding the CD2-binding
protein 1 (CD2BP1) in patients with PAPA syndrome, a rare
autosomal dominant condition characterized by pyogenic
sterile arthritis, PG, and acne (Wise et al, 2002). The
ubiquitously expressed CD2BP1 cytosolic adaptor has
recently been shown to play a key role in regulating the
activation of T cells (Badour et al, 2003). Thus the linkage of
CD2BP1 gene mutation with a clinical syndrome, which
includes PG is consistent with a role for immune cellular
interactions in the genesis of PG.
The discovery that CD2BP1 mutation causes PAPA
syndrome also raises the possibility that CD2BP1 variants
contribute to development of the PG lesions that develop
in association with other systemic diseases. Such diseases
include the inflammatory bowel diseases (IBD), Crohn’s
disease (CD) and ulcerative colitis (UC), for which an
association with PG has been observed in about 1.4%
of affected cases (Bernstein et al, 2001). Recent advances
in delineating the molecular basis of IBD have led to
identification of a susceptibility gene for CD, which encodes
a protein, CARD15, involved in NF-kB activation (Hugot
et al, 2001; Ogura et al, 2001). While the relevance of
CARD15 mutations to CD risk and clinical presentation have
been extensively studied (Ahmad et al, 2002; Newman et al,
in press), their relevance to either CD or UC-associated
extraintestinal manifestations such as PG has not been
reported. The discovery of both CD2BP1 and CARD15
mutations as causes of two diseases associated with PG
and IBD, respectively, raises the possibility that these gene
variants may directly contribute to development of PG. To
investigate this possibility, we examined both CD2BP1 and
CARD15 genotypes in 20 individuals (18 CD and two UC
patients) representing a subset of patients ascertained
through the Mount Sinai Hospital Inflammatory Bowel
Disease Genetics Project (a study approved by the hospital
ethics review board in adherence to the Declaration of
Helsinki guidelines) and diagnosed with PG during the
course of their disease (McLeod et al, 1997). For CD2BP1
genotyping, each of the 15 CD2BP1 exons was amplified
from genomic DNA samples using the oligonucleotide
primer pairs and amplification conditions shown in Table I.
To ensure detection of variant homoduplexes, amplicons
were mixed with one-third volume wild-type PCR products,
denatured, cooled and then subjected to dHPLC analysis
(Wave, Transgenomics, Ohmaha, NE). Sequence variants
identified by dHPLC were then sequenced using the ABI
PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster
City, CA). Reference nucleotide sequence used for evalua-
tion of CD2BP1 mutations was derived from resequencing
of the gene in control individuals and also from the GenBank
sequence (NM_003978). CARD15 genotyping was re-
stricted to analysis of the three CARD15 variants (R702W,
G908R, and fs1007insC) known to account for more than
80% of CD-associated CARD15 mutations (Lesage et al,
2002) and was performed using allele-specific PCR as
previously described (Newman et al, 2003).
Results of CD2BP1 mutation screening and sequencing
revealed the presence of numerous CD2BP1 polymorph-
isms within the patient group, only four of which were
located in coding regions. Among these four coding region
polymorphisms, three were synonymous changes (G543A,
C915T, and G1179A) present in 1%–2% of ethnically
matched healthy controls and predicted to have no func-
tional consequence. In addition, a non-synonymous variant,
a G to A transition at nucleotide position 155, was detected
in one patient. This mutation, however, leads to an amino
acid substitution (R52Q), which does not map within any of
the key functional domains of CD2BP1 and does not alter
transcript splicing (data not shown). Although this variant
was only present in 1 of 600 ethnically matched healthy
controls, it is predicted to be biologically silent by an in silico
algorithm (PolyPhen), which gauges the potential functional
significance of coding region nucleotide substitutions
(Ramensky et al, 2002). These observations, together with
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the failure to detect sequence variants in most of the
patients under study, imply that CD2BP1 mutation is un-
likely to account for PG in IBD patients. Similarly, the
analysis of CARD15 mutations in this patient group revealed
that one CD patient was heterozygous for the G908R vari-
ant and three CD patients were heterozygous for the
fs1007insC among the twenty patients and thus demon-
strated the frequency of CARD15 variant carriage to be no
different among this PG-affected group than in the CD
population in general (Newman et al, in press).
Although our data revealed no significant association of
either CD2BP1 or CARD15 mutation with PG in CD patients,
a number of interesting findings emerged. Overview of our
database of 3373 patients with IBD, revealed a reported
episode of PG in 48 patients (1.4%), an incidence rate
identical to that reported in other studies of IBD extra-
intestinal manifestations (Bernstein et al, 2001). Among
these patients, 35 of 1919 (1.7%) had CD, 13/1413 (0.9%)
UC and two of 40 (5%) indeterminate colitis, a distribution
consistent with the suggestion that PG occurs more
commonly in CD than UC patients (Bernstein et al, 2001).
Previously familial PG has only been reported in idiopathic
cases, one of the IBD families ascertained at Mount Sinai
Hospital included three first-degree CD patients who all
experienced episodes of PG. This supports the possibility
that there is a significant genetic predisposition to PG in
some IBD families and that studies of CD2BP1 and other
candidate genes in idiopathic and secondary PG patients
are warranted. Identification of genetic susceptibility vari-
ants for PG would minimize misdiagnosis of PG, recently
estimated as 10% (Weenig et al, 2002) and may provide
insight into new treatment strategies.
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Table I. Primers for PCR ampliﬁcation prior to DHPLC analysis
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Product size
(bp)
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R: CCTTTGCCTCCTCTGAACTG
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oligonucleotide primers. PCR reactions were performed in 40 mL
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genomic DNA. Amplicons were generated in a GeneAmp 9600 (Perkin-
Elmer, Foster City, California) thermocycler. Amplification conditions were
951C for 12 min followed by 35 cycles of 941C 30 s, 56–581C 30 s, 721C
30 s, and a final extension at 721C for 7 min.
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